Literature DB >> 31042847

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Reply.

Marie Scully1, Jessica Minkue Mi Edou2, Filip Callewaert3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31042847     DOI： 10.1056/NEJMc1902336

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.

Authors:  Jingrui Sui; Ruinan Lu; Konstantine Halkidis; Nicole K Kocher; Wenjing Cao; Marisa B Marques; X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-01-03       Impact factor: 5.824

2.  Clinical relapse of immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination.

Authors:  William Deucher; Senthil Sukumar; Spero R Cataland
Journal:  Res Pract Thromb Haemost       Date:  2022-02-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.